Decoy Therapeutics Inc. 8-K

What Happened

• Decoy Therapeutics Inc. announced on May 12, 2026 that its 2026 Annual Meeting of Stockholders will be held on July 14, 2026. The company filed an 8-K on May 19, 2026 to report the meeting date and related procedural deadlines.
• Stockholders of record at the close of business on May 22, 2026 will be entitled to notice of and to vote at the 2026 Annual Meeting. Because the meeting date differs from last year’s meeting by more than 30 days, the company notified shareholders under Rule 14a-5(f) of the Exchange Act.

Key Details

• Annual Meeting date: July 14, 2026. Record date for voting: May 22, 2026.
• Deadline for shareholder proposals under Rule 14a-8 (to be included in proxy materials): close of business on May 29, 2026.
• Deadline for advance-notice proposals or director nominations under the company’s Bylaws and for universal-proxy Rule 14a-19 compliance: close of business on May 29, 2026. Deliver proposals to: Decoy Therapeutics Inc., Attn: Secretary, 2450 Holcombe Blvd., Suite X, Houston, TX 77021.
• Filing signed May 19, 2026 by Mark J. Rosenblum, Executive VP & Chief Financial Officer.

Why It Matters

• Investors who want to vote at the meeting must be shareholders of record by May 22, 2026.
• Shareholders who want to submit proposals for the proxy statement or nominate directors must meet the May 29, 2026 deadlines and follow SEC Rule 14a-8, the company’s Bylaws, and (if soliciting proxies for competing nominees) Rule 14a-19 universal proxy requirements—missing these deadlines generally means a proposal or nominee will not appear in the company’s proxy materials.
• These procedural dates affect how shareholders can influence corporate governance, propose business, or run director nomination campaigns ahead of the July meeting.